Pitavastatin Reduces Major Atherosclerotic Cardiovascular Events in Adults with HIV.

IF 2.6 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of the American Board of Family Medicine Pub Date : 2025-09-15 DOI:10.3122/jabfm.2025.250014R0

Kathryn K Garner, Chris Colvin, Brock Cardon

引用次数: 0

Abstract

Initiation of pitavastatin in adults aged 40 to 75 living with HIV treated with highly active antiretroviral therapy (HAART) with low-to-moderate 10-year atherosclerotic cardiovascular disease (ASCVD) risk decreases the incidence of major cardiovascular events (MACE).

查看原文本刊更多论文

匹伐他汀可降低成人HIV患者的主要动脉粥样硬化性心血管事件。

在接受高效抗逆转录病毒治疗（HAART）且10年低至中度动脉粥样硬化性心血管疾病（ASCVD）风险的40 - 75岁艾滋病毒感染者中，开始使用匹伐他汀可降低主要心血管事件（MACE）的发生率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Board of Family Medicine 医学-医学：内科

CiteScore

4.90

自引率

6.90%

发文量

168

审稿时长

4-8 weeks

期刊介绍： Published since 1988, the Journal of the American Board of Family Medicine ( JABFM ) is the official peer-reviewed journal of the American Board of Family Medicine (ABFM). Believing that the public and scientific communities are best served by open access to information, JABFM makes its articles available free of charge and without registration at www.jabfm.org. JABFM is indexed by Medline, Index Medicus, and other services.